PR Newswire
ROCKVILLE, Md., Feb. 20, 2019
ROCKVILLE, Md., Feb. 20, 2019 /PRNewswire/ -- REGENXBIO
Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of
gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a conference call on
Wednesday, February 27, 2019, at 4:30 p.m. ET to discuss its
financial results for the quarter and full-year ended December 31, 2018, and recent operational
highlights.
To access the live call by phone, dial (855) 422-8964 (domestic) or (210) 229-8819 (international) and enter the passcode
1564206. To access a live or recorded webcast of the call, please visit the Investors section of the REGENXBIO website at
www.regenxbio.com. The recorded webcast will be available for approximately 30 days following the call.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene
therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of
exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV
Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in
multiple therapeutic areas.
Contacts:
Investors:
Heather Savelle, 212-600-1902
heather@argotpartners.com
Media:
David Rosen, 212-600-1902
david.rosen@argotpartners.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-february-27-to-discuss-fourth-quarter-and-full-year-2018-financial-results-and-recent-operational-highlights-300798424.html
SOURCE REGENXBIO Inc.